CYTK Stock News 4.42 05/13/2014 18:36:22 Cytokinetics Inc (C

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cytokinetics Inc (CYTK) 4.42 $CYTK

Hypertension - Pipeline Review, H1 2014: 48 Conipanies and 94 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h24nbf/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Companies Involved: - AFFiRiS AG - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Ahn-Gook Pharmaceutical Co., Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - Anacor Pharmaceuticals, Inc. - AngioDesign - Arromax Pharmatech, Co. Ltd. - Bayer AG - BioLineRx, Ltd. - Biocon Limited - Biolink Group AS - CJ CheilJedang Corp. - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - Cyano Biotech GmbH - Cytokinetics, Incorporated - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - NanoForm Therapeutics Ltd. - Novartis AG - Palatin Technologies, Inc. - QUANTUM GENOMICS Corp. - RedHill Biopharma Ltd. - Sanofi - Takeda Pharmaceutical Company Limited - Toray Industries, Inc. - Torrent Pharmaceuticals Limited Drug Profiles: - azilsartan medoxomil - carvedilol CR - (rosuvastatin telmisartan) - (irbesartan atorvastatin calcium) - (rosuvastatin calcium olmesartan medoxomil) - ZV Combi - pratosartan - carvedilol CR - (rosuvastatin calcium olmesartan medoxomil) - (rosuvastatin valsartan) - CKD-825 - (losartan potassium hydrochlorothiazide amlodipine besylate) - XY-1014-KD-2 - PL-3994 - (atorvastatin calcium losartan potassium) - KD-027 - CS-3150 - (simvastatin Immediate Release amlodipine maleate Delayed Release) - LFF-269 - Potassium Magnesium Citrate - pratosartan - dextromethorphan - QGC-001 - HPT-C/D-3G - (amlodipine besylate losartan potassium) - (simvastatin losartan potassium) - (simvastatin Immediate Release amlodipine maleate Delayed Release) - (candesartan amlodipine besylate) - TAK-272 - MK-7145 IR For more information visit http://www.researchandmarkets.com/research/h2...pertension

Cytokinetics, Incorporated Reports First Quarter 2014 Financial Results
Thomson Reuters ONE - Tue May 06, 3:03PM CDT
Company Considers Potential Next Steps for First-in-Class Skeletal Muscle Activator Focused to ALS

Biotech Stocks Scanner -- Research on PDL BioPharma, Cytokinetics, Vical, and Peregrine Pharma
PR Newswire - Tue May 06, 11:41AM CDT
The markets on Monday, May 05, 2014 ended on a higher note as the S&P 500 finished the session 0.19% higher at 1,884.66, and the NASDAQ Composite closed at 4,138.06, up 0.34%. The Dow Jones Industrial Average finished at 16,530.55, up 0.11%. During the session, the eight out of ten sectors ended in positive. During the session gains in the Utilities, Health Care, and Materials sectors positively impacted the broader market, while some retraction came in from Consumer Staples and Financials sectors. The S&P 500 Health Care Sector Index closed the day at 672.57, up 0.56%, with the index also advancing 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Cytokinetics Inc. (NASDAQ: CYTK), Vical Inc. (NASDAQ: VICL) and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free technical research on PDLI, CYTK, VICL and PPHM can be downloaded upon signing up at:

Biotech 101: Valuing Binary Events
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:18PM CDT
Binary events are the lifeblood of investing in biotech companies. A clinical trial result or Food and Drug Administration decision can send the company's value up or down considerably. And not necessarily the same amount in either direction; the...

Clinical Winners and Losers: Spectrum Pharmaceuticals and Cytokinetics
Cory Renauer, The Motley Fool - Motley Fool - Fri May 02, 8:30AM CDT
Clinical trial highlights took a back seat last week to the stream of blockbuster deals in the health care sector. Still, there was a big winner and a big loser -- even if they flew relatively under the radar.  Spectrum Pharmaceuticals  was, in my...

Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.

Dueling Analysts on Cytokinetics: ALS Drug is 'Finished' or a 'Ray of Sunshine'
at The Street - Tue Apr 29, 10:24AM CDT
Two sell-side analysts with very different views Tuesday on Cytokinetics and its experimental ALS drug tirasemtiv.

Global Cachexia Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pggqhv/cachexia) has announced the addition of the "Cachexia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cachexia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cachexia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cachexia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - GlaxoSmithKline plc - Plexxikon Inc. - BioLineRx, Ltd. - Novartis AG - Aphios Corporation - Calzada Limited - Palatin Technologies, Inc. - Cytokinetics, Incorporated - Fate Therapeutics, Inc. - AVEO Pharmaceuticals, Inc. - Fountain Biopharma Inc. - Rhythm Pharmaceuticals - MI.TO. Technology S.r.L. For more information visit http://www.researchandmarkets.com/research/pggqhv/cachexia

Cytokinetics Announces Additional Results from BENEFIT-ALS
Thomson Reuters ONE - Tue Apr 29, 6:31AM CDT
First Clinical Trial in Patients with ALS to Show a Significant Reduction in Decline of Slow Vital Capacity

Cytokinetics' Tirasemtiv Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 2:22PM CDT
Shares of Cytokinetics tumbled 64.7% after it announced that tirasemtiv failed to meet its primary endpoint in the phase IIb, BENEFIT-ALS study.

Hot Stock: Cytokinetics, Shares Drop 5.3% (CYTK)
Comtex SmarTrend(R) - Mon Apr 28, 10:11AM CDT
Cytokinetics (NASDAQ:CYTK) is one of today's worst performing low-priced stocks, down 5.3% to $4.35 on 1.6x average daily volume. Thus far today, Cytokinetics has traded 1.9 million shares, vs. average volume of 1.2 million shares per day. The stock has underperformed the Dow (-5.3% to the Dow's 0.7%) and underperformed the S&P 500 (-5.3% to the S&P's 0.5%) during today's trading.

This Week in Biotech: Is This the Return of Big M&A?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 26, 2:15PM CDT
With the  SPDR S&P Biotech Index  up  18% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...

Why Cytokinetics (CYTK) Stock Is Plummeting Today (Update)
at The Street - Fri Apr 25, 3:20PM CDT
Cytokinetics (CYTK) plummeted more than 60% to a one-year low of $4.96 on Friday after the biotechnology company announced its experimental treatment for Lou Gehrig's disease failed to meet its primary goal in a mid-stage trial.

Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 25, 12:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:

Why Cytokinetics Inc. Shares Were Mauled
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 25, 12:00PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Cytokinetics , a clinical-stage...

Is There Value In Cytokinetics Following Its 60% Drop?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 25, 10:50AM CDT
Big money can be made in owning promising pipelines, but only if trial data validates the hope. In the case of Cytokinetics , hope was dashed when the company reported its drug for ALS, also known as Lou Gehrig's Disease, failed to meet its primary...

Cytokinetics skids after ALS drug fails in study
AP - Fri Apr 25, 10:02AM CDT
NEW YORK (AP) — Shares of Cytokinetics lost more than half their value Friday after the drug developer said an experimental treatment for Lou Gehrig's disease failed to slow the fatal condition's progression more than a placebo in a clinical trial.

Cytokinetics Announces Top-Line Results From BENEFIT-ALS
Thomson Reuters ONE - Fri Apr 25, 6:31AM CDT
Company Summarizes Initial Data From Phase IIb Clinical Trial of Tirasemtiv

Cytokinetics to Announce First Quarter Results on May 6, 2014
Thomson Reuters ONE - Thu Apr 24, 3:40PM CDT
South San Francisco, CA., April 24, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report first quarter results on Tuesday, May 6, 2014 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 287

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Cambrian Turns Dairy Wastewater Into Long-Term Gas

Updated Category News Views 15

A Wisconsin dairy plant just traded lagoon duty for a 20-year service arrangement, and that is more consequential than the usual shiny renewable-gas headline. Cambrian Innovation says it has commissioned and is operating a wastewater treatment and resource recovery system that handles roughly 280,000 gallons a day. That works out to about 102 million gallons annually, a...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 71

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 102

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 210

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 56

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 180

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Wealth Forum Puts AI and Tokenisation Before Private Wealth

Updated Category News Views 63

Private wealth is about to get squeezed from three directions at once: younger heirs, smarter machines and assets that do not fit neatly in the old family-office binder. That is the real backdrop to the Future of Wealth Forum, a new GFTN and Luxembourg House of Financial Technology partnership slated for Luxembourg City on September 27-29, 2027. It is early days,...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 164

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading

Top 5 Most Recently Viewed Articles

United Bank Secures Crucial $75M Tax Credit for Growth

Updated Category News Views 148

United Bank Receives Significant Tax Credit Allocation United Bank is excited to share that it has been awarded a substantial allocation of $75 million under the New Markets Tax Credit (NMTC) program. This funding, granted by the Department of the Treasury through its affiliated Community Development Entity, UB Community Development, is a testament to the bank's ongoing...

Continue Reading
Exploring Intangible Assets in ASEAN Capital Markets

Updated Category News Views 245

Understanding Intangible Assets in ASEAN Capital Markets Global consulting firm J.S. Held has collaborated with notable organizations to produce an insightful report examining the landscape of intangible assets in ASEAN capital markets. This partnership involves the International Valuation Standards Council (IVSC), the Intellectual Property Office of Singapore (IPOS), and...

Continue Reading
Festival Celebrates Community with Food and Support Services

Updated Category News Views 180

Union Station Homeless Services Teams with Boomtown Brewery Union Station Homeless Services (USHS) collaborates with Boomtown Brewery for a vibrant Summer Sampler Food Festival. This delightful event will showcase not just delicious food but also the spirit of community and cooperation. A Flavorful Afternoon to Remember Taking center stage will be the wide array of...

Continue Reading
Flowable Showcases Cutting-Edge AI Solutions at Gartner Event

Updated Category News Views 260

Flowable Presents Innovative AI Solutions at Gartner Symposium Flowable CEO and CTO to Showcase Responsible AI-Driven Solutions Flowable, a leader in intelligent automation and enterprise transformation, is set to exhibit and present at the renowned Gartner IT Symposium/Xpo 2025 in Barcelona, Spain. This significant gathering of IT professionals will take place from...

Continue Reading
Accounts Receivable Automation Market Set for Major Growth

Updated Category News Views 214

Transforming Financial Management: The Rise of Accounts Receivable Automation As businesses seek operational excellence, the Accounts Receivable (AR) automation market is on a remarkable upswing. It's set to hit USD 3.8 billion by 2033, sporting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2033. This trend signifies a notable change in how companies handle...

Continue Reading